IFGL Refractories Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/gu5rpzv2v5semdxufc5i8jz1.pdf

Key Takeaways


Domestic Engine vs. International Headwinds

Arasu Shanmugam: "We all know that once you have a basket of full range, then it helps us in managing internally the risk even if one area falls and other area picks up. So it helps in delivering a consistent performance as a company."

Margin Compression: The Triple Squeeze

Arasu Shanmugam: "That's temporary if you look at the future growth and potential that we've explained, and this is a normal preparation with any business has to do we're doing and we're very, very optimistic about bringing the percentage of employee cost to the normal."

The Marvels JV: A Path-Breaking Diversification

Arasu Shanmugam: "This IFGL Marvels JV that I would say it is going to be a really path breaking movement for IFGL. Why do I say so? Because our diversification into non-steel market so far historically IFGL heavily dependent on steel."

International Restructuring: Rebuilding for a Recovery

James McIntosh: "Thus we see as a positive and we think this will give both of our American companies a leg up."

Capacity Build-Out and New Product Launches


Near-Term Outlook: A Holding Pattern


Guidance & Commitments

CommitmentSpecificsTimeline
Margin recoveryConfident to address margin situation through customer pass-through discussionsEnd of Q1 FY26
Marvels JV plant commissioningGreenfield state-of-the-art plant in GujaratMarch 2026
Marvels JV commercial productionProduction commencement, ramp to 40% in 4 months, 90% in 2 yearsH2 FY27
Magnesia bricks and casting flux contributionNew products to start contributing revenueQ1 FY26 onwards
Sheffield technology transferSetup to land in India, implementation from MayEnd April 2025
Non-ferrous revenue targetNon-ferrous to contribute 15% of total revenueWithin 5 years
US consolidation payoffCombined facility to deliver fairly healthy growthOver next couple of years
FY26 guidanceWill issue formal guidanceNext quarter

Key Metrics

MetricQ3 FY25
Consolidated total income₹382 cr, +3% YoY
Standalone total income₹235 cr, +18% YoY
Standalone total income (9M FY25)₹740 cr, +7% YoY
Consolidated EBITDA₹19 cr
Consolidated EBITDA margin5.1%
Consolidated EBITDA margin (9M FY25)9%
Standalone EBITDA₹22.2 cr
Standalone EBITDA margin9.4%
Standalone EBITDA margin (9M FY25)13.5%
Consolidated loss₹2 cr
Standalone PAT₹5 cr
Standalone PAT (9M FY25)₹40.7 cr
Domestic business revenue (9M FY25)₹518 cr, +18% YoY, 71% of standalone revenue
Exports business revenue (9M FY25)₹209 cr, -15% YoY, 29% of standalone revenue
Domestic made and domestic sold revenue growth26% YoY
Indian business growthover 25% YoY
Indian business growth (9M FY25)18% YoY
Net debt₹11.64 cr
Cash and cash equivalents (consolidated)₹180 cr as of Dec '25
Annualized ROCE6.5%
Annualized ROE4.2%
Capex spent in FY25₹160–170 cr
Non-ferrous revenue (FY25)₹15 cr, first entry from zero previous year
Employee benefit cost (consolidated)₹70 cr for the quarter
Marvels JV plant capacity25,000 tons per year, revenue addition of ₹48–50 cr at today's pricing, contribution from H2 FY27
Vizag business revenue (FY25)₹160 cr, more than doubled from ₹72 cr in FY24, expected to exceed ₹220 cr next year